Why the study?
Does clonidine therapy alter norepinephrine kinetics and reduce diaphoretic episodes in Shapiro's syndrome?
Does clonidine therapy alter norepinephrine kinetics and reduce diaphoretic episodes in Shapiro's syndrome?
Clonidine may provide effective treatment for Shapiro's syndrome by normalizing altered norepinephrine kinetics.
Hypothesis-generating for clonidine in Shapiro's syndrome; leaves open efficacy, durability, and safety pending controlled trials.
We studied a 66-year-old woman with spontaneous periodic hypothermia (Shapiro's syndrome) to determine the mechanisms that result in increased plasma norepinephrine (NE) levels. In comparison with age-matched control subjects, compartmental analysis of NE kinetics revealed an increased NE release rate into the extravascular compartment and decreases in NE clearance and volume of distribution of NE in the intravascular compartment. Clonidine therapy was associated with an initial dramatic decrease in the frequency of diaphoretic episodes as well as with a fall in NE release rate and increases in NE clearance and volume of distribution. We conclude that increased NE release and decreased plasma NE clearance result in elevated plasma NE levels in Shapiro's syndrome. Clonidine, which was associated with changes in NE kinetics, may provide effective treatment for this disorder.
No takes yet. Share an insight, caveat, or question.
Sanfield et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: